3. (individual commitment) CHAI will commit full-time staff to assist EGPAF, WHO, PEPFAR, UNITAID and others to develop, coordinate and implement a detailed work plan to achieve the goals of the initiative; to assist with reaching agreements with companies, governments, donors and regulators to accelerate the introduction of optimal formulations and diagnostics for children and adolescents both short term and long term; and to work with governments and faith based organizations to scale up identification and treatment of HIV infected children and adolescents in the target countries.
CHAI has developed draft plans to accelerate in-country uptake of new pediatric ARVs in collaboration with other stakeholders.
Update on pediatrics DTG: All activities are on track including confidential, official correspondence with the FDA regarding the filing strategy for the DTG 10 mg scored DT.
CHAI is implementing the FASTER project under the leadership of Catholic Relief Services, funded by PEPFAR through CDC. This is an initiative between government, civil society organizations, FBOs and others to catalyze progress towards achieving 95-95-95 targets for children and adolescents. FASTER is being implemented in Nigeria, Uganda, Tanzania, Zambia, and Zimbabwe. The project focuses on 6 priority actions across the pediatric and adolescent testing and treatment cascade, agreed upon by a core set of stakeholders as a follow up to the 2017 Rome Action Plan. FASTER has also supported early GAP-f activities through support to the secretariat and expects to continue doing so until FY’21.
42. Support POC EID as well as case-finding through enhanced testing in inpatient, TB, and nutrition wards through the development of clear policies as well as program and operational guidance, and through implementation support.
43. Promote broader uptake of new sample types for laboratory systems and multiplex testing to improve cost efficiencies.
44. Invest in data management to provide more visibility to optimized laboratory networks for faster corrective actions and better quality testing.
45. Support Country Governments with 1) the latest data on performance and regulatory status of new diagnostics; 2) implementation of global guidance on product approvals and post market surveillance; and 3) once the WHO Collaborative Procedure for IVDs is established, promote rapid adoption, shifting the focus of quality assurance to post-market instead of pre-market.
46. Support the development of programmatic and operational guidance on POC VL for children, adolescents, and pregnant and breastfeeding women including by building evidence to support these policies.
Working with CRS on in-country registration processes; building a consolidated database on paediatric diagnostic guidelines and technical evaluations with WHO and ASLM.
32. Collaborate with WHO to house and incubate the GAP-f partnership through its start-up phase.